289 related articles for article (PubMed ID: 27988109)
1. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
2. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies.
Appiah-Kubi K; Lan T; Wang Y; Qian H; Wu M; Yao X; Wu Y; Chen Y
Crit Rev Oncol Hematol; 2017 Jan; 109():20-34. PubMed ID: 28010895
[TBL] [Abstract][Full Text] [Related]
4. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases.
Toffalini F; Demoulin JB
Blood; 2010 Oct; 116(14):2429-37. PubMed ID: 20581310
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between tyrosine kinase receptors, GSK3 and BMP2 signaling during osteoblastic differentiation of human mesenchymal stem cells.
Biver E; Thouverey C; Magne D; Caverzasio J
Mol Cell Endocrinol; 2014 Jan; 382(1):120-130. PubMed ID: 24060635
[TBL] [Abstract][Full Text] [Related]
6. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.
Mariño-Enríquez A; Dal Cin P
Cancer Genet; 2013 Nov; 206(11):357-73. PubMed ID: 24091028
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
8. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Niederst MJ; Engelman JA
Sci Signal; 2013 Sep; 6(294):re6. PubMed ID: 24065147
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic receptor tyrosine kinase in leukemia.
Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
[TBL] [Abstract][Full Text] [Related]
10. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
Cross MJ; Lu L; Magnusson P; Nyqvist D; Holmqvist K; Welsh M; Claesson-Welsh L
Mol Biol Cell; 2002 Aug; 13(8):2881-93. PubMed ID: 12181353
[TBL] [Abstract][Full Text] [Related]
11. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
12. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Singh H; Li YY; Spurr LF; Shinagare AB; Abhyankar R; Reilly E; Brais LK; Nag A; Ducar MD; Thorner AR; Shapiro GI; Keller RB; Siletti C; Clark JW; Farago AF; Lin JJ; Demetri GD; Gujrathi R; Kulke MH; MacConaill LE; Ligon AH; Sicinska E; Meyerson ML; Meyerhardt JA; Cherniack AD; Wolpin BM; Ng K; Giannakis M; Hornick JL; Cleary JM
Clin Cancer Res; 2021 Mar; 27(6):1695-1705. PubMed ID: 33414136
[TBL] [Abstract][Full Text] [Related]
14. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
15. Phylogenetic and transcriptomic characterization of insulin and growth factor receptor tyrosine kinases in crustaceans.
Flores KA; Pérez-Moreno JL; Durica DS; Mykles DL
Front Endocrinol (Lausanne); 2024; 15():1379231. PubMed ID: 38638139
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase in human cancer.
Barreca A; Lasorsa E; Riera L; Machiorlatti R; Piva R; Ponzoni M; Kwee I; Bertoni F; Piccaluga PP; Pileri SA; Inghirami G;
J Mol Endocrinol; 2011 Aug; 47(1):R11-23. PubMed ID: 21502284
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase fusion genes in chronic myeloproliferative diseases.
Cross NC; Reiter A
Leukemia; 2002 Jul; 16(7):1207-12. PubMed ID: 12094244
[TBL] [Abstract][Full Text] [Related]
18. Mactosylceramide prevents glial cell overgrowth by inhibiting insulin and fibroblast growth factor receptor signaling.
Gerdøe-Kristensen S; Lund VK; Wandall HH; Kjaerulff O
J Cell Physiol; 2017 Nov; 232(11):3112-3127. PubMed ID: 28019653
[TBL] [Abstract][Full Text] [Related]
19. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
